Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic

Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic Publisher Pubmed

Ghajarzadeh M¹ ; Mirmosayyeb O^{1, 2, 3} ; Barzegar M^{2, 3} ; Nehzat N^{1, 3} ; Vaheb S³ ; Shaygannejad V^{2, 3} ; Maghzi AH⁴

Show Affiliations

1. Universal council of epidemiology (UCE), universal scientific education and research network (USERN), Tehran University of medical sciences, Tehran, Iran
2. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4. Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States

Source: Multiple Sclerosis and Related Disorders Published:2020

Abstract

[No abstract available]

Related Docs

1. Characteristics of Covid-19 Disease in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)

2. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)

3. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)

4. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic, Biomolecules (2021)

5. Covid-19 Among Patients With Multiple Sclerosis a Systematic Review, Neurology: Neuroimmunology and NeuroInflammation (2021)

6. Covid-19 Infection and Hospitalization Rate in Iranian Multiple Sclerosis Patients: What We Know by May 2021, Multiple Sclerosis and Related Disorders (2022)

7. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)

8. A Multi-Centre Longitudinal Study Analysing Multiple Sclerosis Disease-Modifying Therapy Prescribing Patterns During the Covid-19 Pandemic, Journal of Neurology (2024)

Experts (# of related papers)

View all Related Experts

Vahid Shaygannejad (5)

Fereshteh Ashtari (2)

Style	Citing Format
MLA	Ghajarzadeh M, et al.. "Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic." Multiple Sclerosis and Related Disorders, vol. 43, no. , 2020, pp. -.
APA	Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH (2020). Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic. Multiple Sclerosis and Related Disorders, 43(), -.
Chicago	Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. "Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic." Multiple Sclerosis and Related Disorders 43, no. (2020): -.
Harvard	Ghajarzadeh M et al. (2020) 'Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic', Multiple Sclerosis and Related Disorders, 43(), pp. -.
Vancouver	Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V, et al.. Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic. Multiple Sclerosis and Related Disorders. 2020;43():-.
BibTex	@article{ author = {Ghajarzadeh M and Mirmosayyeb O and Barzegar M and Nehzat N and Vaheb S and Shaygannejad V and Maghzi AH}, title = {Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic}, journal = {Multiple Sclerosis and Related Disorders}, volume = {43}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Ghajarzadeh M AU - Mirmosayyeb O AU - Barzegar M AU - Nehzat N AU - Vaheb S AU - Shaygannejad V AU - Maghzi AH TI - Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic JO - Multiple Sclerosis and Related Disorders VL - 43 IS - SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract